{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:52:10Z","timestamp":1791492730596,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaip.2026.08.027","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:27:47Z","timestamp":1787930867000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-Lowering Medications Increase the Severity of Hymenoptera Venom Anaphylaxis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4272-3055","authenticated-orcid":false,"given":"Kaylee","family":"Sohng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Matz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan","family":"Thapaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Masuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"D\u00f6lle-Bierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Alix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.08.027_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.08.027_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2012.08.016","article-title":"Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis","volume":"131","author":"Vadas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000141516","article-title":"PAF, rather than histamine, participates in mouse anaphylactic hypotension","volume":"82","author":"Shibamoto","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.jaip.2026.08.027_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2016.01.034","article-title":"The responses of pulmonary and systemic circulation and airway to anaphylactic mediators in anesthetized BALB\/c mice","volume":"147","author":"Wang","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.jaip.2026.08.027_bib5","first-page":"175","article-title":"Changes of prostaglandin D2, carboxypeptidase A3 and platelet activating factor in guinea pig in anaphylactic shock","volume":"28","author":"Yang","year":"2012","journal-title":"J Forensic Med"},{"key":"10.1016\/j.jaip.2026.08.027_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/cea.13540","article-title":"Treatment with a platelet-activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock","volume":"50","author":"Tacquard","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.08.027_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1164\/ajrccm\/147.5.1223","article-title":"The effects of combined histamine and platelet-activating factor antagonism on systemic anaphylaxis induced by immunoglobulin E in the rabbit","volume":"147","author":"Lohman","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2026.08.027_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaci.2009.03.012","article-title":"Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions","volume":"124","author":"Arias","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0090-6980(88)90135-9","article-title":"Antagonism of PAF-induced death in mice","volume":"35","author":"Myers","year":"1988","journal-title":"Prostaglandins"},{"key":"10.1016\/j.jaip.2026.08.027_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1084\/jem.187.11.1779","article-title":"Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor","volume":"187","author":"Ishii","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaip.2026.08.027_bib11","doi-asserted-by":"crossref","first-page":"52762","DOI":"10.1039\/C7RA09268G","article-title":"Epinephrine inhibits vascular hyperpermeability during platelet-activating factor- or ovalbumin-induced anaphylaxis","volume":"7","author":"Ma","year":"2017","journal-title":"RSC Adv"},{"key":"10.1016\/j.jaip.2026.08.027_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1710-1492-10-20","article-title":"Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy","volume":"10","author":"Perelman","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(99)00920-6","article-title":"Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models","volume":"390","author":"Fukuda","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaip.2026.08.027_bib14","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1172\/JCI118733","article-title":"Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase","volume":"97","author":"Stafforini","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2026.08.027_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/(SICI)1096-8652(199611)53:3<158::AID-AJH2>3.0.CO;2-Y","article-title":"Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells","volume":"53","author":"Yoshida","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.08.027_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI5574","article-title":"Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma","volume":"103","author":"Stafforini","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2026.08.027_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00003246-199402000-00009","article-title":"Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis","volume":"22","author":"Graham","year":"1994","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaip.2026.08.027_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2013.06.015","article-title":"Anaphylaxis: clinical patterns, mediator release, and severity","volume":"132","author":"Brown","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib19","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2013.10.033","article-title":"Basal platelet-activating factor acetylhydrolase: prognostic marker of severe Hymenoptera venom anaphylaxis","volume":"133","author":"Pravettoni","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib20","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/all.15308","article-title":"Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children","volume":"77","author":"Upton","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.08.027_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0009-8981(01)00612-X","article-title":"Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese","volume":"312","author":"Kosaka","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaip.2026.08.027_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/hq0202.102918","article-title":"Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB","volume":"22","author":"Tsimihodimos","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaip.2026.08.027_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/01.CIR.0000072791.40232.8F","article-title":"Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction","volume":"108","author":"Ben\u00edtez","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaip.2026.08.027_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diabres.2009.04.016","article-title":"Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus","volume":"85","author":"Gomes","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jaip.2026.08.027_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1582-4934.2002.tb00462.x","article-title":"Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus","volume":"6","author":"Serban","year":"2002","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jaip.2026.08.027_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.14740\/jocmr3901","article-title":"Ezetimibe monotherapy reduces serum levels of platelet-activating factor acetylhydrolase in patients with dyslipidemia","volume":"11","author":"Tano","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jaip.2026.08.027_bib27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0022-2275(20)34942-7","article-title":"Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins","volume":"38","author":"Guerra","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaip.2026.08.027_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2125.2006.02832.x","article-title":"Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients","volume":"63","author":"Kom","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2026.08.027_bib29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1210\/jc.2003-031494","article-title":"Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes","volume":"89","author":"Winkler","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaip.2026.08.027_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1194\/jlr.M200452-JLR200","article-title":"Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins","volume":"44","author":"Tsimihodimos","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaip.2026.08.027_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/all.13380","article-title":"Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the European Anaphylaxis Registry","volume":"73","author":"Worm","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.08.027_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2018.10.042","article-title":"Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies","volume":"7","author":"Tejedor-Alonso","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.08.027_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.anai.2017.07.014","article-title":"Risk factors for severe anaphylaxis in the United States","volume":"119","author":"Motosue","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib35","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/all.12426","article-title":"Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis","volume":"69","author":"Reitter","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.08.027_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/cea.12520","article-title":"Anaphylaxis and cardiovascular disease: therapeutic dilemmas","volume":"45","author":"Lieberman","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2026.08.027_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2013.01.011","article-title":"Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis","volume":"131","author":"Lee","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2020.06.008","article-title":"Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry","volume":"147","author":"Francuzik","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.08.027_bib39","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/all.14785","article-title":"\u03b2-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy","volume":"76","author":"Sturm","year":"2021","journal-title":"Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826007208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:47:57Z","timestamp":1791492477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826007208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S2213219826007208"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.08.027","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-Lowering Medications Increase the Severity of Hymenoptera Venom Anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}